Otsuka
Updates & Highlights
simplywall.st · about 1 month ago
Otsuka (TSE:4768) Could Be 9% Below Fair Value On Raised Guidance And Dividends
biocentury.com · about 1 month ago
Otsuka’s Voyxact raises the bar in IgA nephropathy
simplywall.st · about 1 month ago
How Upgraded Earnings Guidance And Higher Dividends At Otsuka (TSE:4768) Has Changed Its Investment Story
Recent Openings
View all 2 jobs arrow_forwardAll Jobs
Culture & Mission
Benefits & Perks
Equity/Stock Options
Ownership in the company
Health Insurance
Medical, dental & vision
Learning Budget
Professional development
Generous PTO
Paid time off
Competitive Salary
Market-rate compensation
Remote Work
Work from anywhere flexibility
Tech Stack
Core Values
Innovation
Pushing boundaries in AI/ML technology
Collaboration
Working together to achieve more
Excellence
Striving for the highest quality
Impact
Making a difference in the world
Office Locations
Team
Are you on the team at Otsuka?
Claim this company page to verify ownership, edit details, and respond to applicants.
Claim this company arrow_forwardNews & Press
20 recentOtsuka (TSE:4768) Could Be 9% Below Fair Value On Raised Guidance And Dividends
Otsuka (TSE:4768) Could Be 9% Below Fair Value On Raised Guidance And Dividends
simplywall.st · about 1 month ago
Otsuka’s Voyxact raises the bar in IgA nephropathy
Otsuka’s Voyxact raises the bar in IgA nephropathy
biocentury.com · about 1 month ago
How Upgraded Earnings Guidance And Higher Dividends At Otsuka (TSE:4768) Has Changed Its Investment Story
How Upgraded Earnings Guidance And Higher Dividends At Otsuka (TSE:4768) Has Changed Its Investment Story
simplywall.st · about 1 month ago
INTERVIEW: Aoi Yuki and Takeo Otsuka, Bringing Maomao and Jinshi to Animated Life in “The Apothecary Diaries”
INTERVIEW: Aoi Yuki and Takeo Otsuka, Bringing Maomao and Jinshi to Animated Life in “The Apothecary Diaries”
Animation Scoop · about 1 month ago
Otsuka Corporation Just Beat EPS By 14%: Here's What Analysts Think Will Happen Next
Otsuka Corporation Just Beat EPS By 14%: Here's What Analysts Think Will Happen Next
simplywall.st · about 1 month ago
Will Otsuka’s Upgraded 2026 Guidance and Higher Dividend Change Otsuka Holdings' (TSE:4578) Narrative?
Will Otsuka’s Upgraded 2026 Guidance and Higher Dividend Change Otsuka Holdings' (TSE:4578) Narrative?
simplywall.st · about 1 month ago
Price to sales forward of Otsuka Holdings Co., Ltd. – SWB:OS1
Price to sales forward of Otsuka Holdings Co., Ltd. – SWB:OS1
TradingView · about 1 month ago
Otsuka's VOYXACT hits VISIONARY two-year eGFR goal in IgA nephropathy
Otsuka's VOYXACT hits VISIONARY two-year eGFR goal in IgA nephropathy
Dealroom · about 1 month ago
Otsuka (TSE:4768) Stock Climbs On Steady EPS As Margins Stay Tight
Otsuka (TSE:4768) Stock Climbs On Steady EPS As Margins Stay Tight
simplywall.st · about 1 month ago
Otsuka’s Voyxact stabilised kidney function at two years in Phase III IgAN trial
Otsuka’s Voyxact stabilised kidney function at two years in Phase III IgAN trial
Yahoo · about 1 month ago
Otsuka reports VOYXACT phase 3 eGFR gain in IgA nephropathy
Otsuka reports VOYXACT phase 3 eGFR gain in IgA nephropathy
International Business Times · about 1 month ago
The Shift: A Path Forward in Depression Care Featuring Otsuka Precision Health
The Shift: A Path Forward in Depression Care Featuring Otsuka Precision Health
HLTH · about 1 month ago
Otsuka Presents Positive Interim Phase 3 VISIONARY eGFR Data Show
Otsuka Presents Positive Interim Phase 3 VISIONARY eGFR Data Show
The National Law Review · about 1 month ago
Otsuka Sponsors the 20th Asian Games Aichi-Nagoya 2026 Supporting Conditioning and Performance with the Global Brand POCARI SWEAT｜August 4, 2026｜News Releases | Otsuka Pharmaceutical Co., Ltd.
Otsuka Sponsors the 20th Asian Games Aichi-Nagoya 2026 Supporting Conditioning and Performance with the Global Brand POCARI SWEAT｜August 4, 2026｜News Releases | Otsuka Pharmaceutical Co., Ltd.
otsuka.co.jp · about 1 month ago
Otsuka Unveils Unprecedented Phase 3 VISIONARY Two-Year eGFR Results Demonstrating VOYXACT® (sibeprenlimab-szsi) Stabilizes Kidney Function Decline to Baseline Physiologic Rate, Fundamentally Altering Disease Progression in IgA Nephropathy
Otsuka Unveils Unprecedented Phase 3 VISIONARY Two-Year eGFR Results Demonstrating VOYXACT® (sibeprenlimab-szsi) Stabilizes Kidney Function Decline to Baseline Physiologic Rate, Fundamentally Altering Disease Progress...
Business Wire · about 1 month ago
In a first, Otsuka’s Voyxact stabilizes IgAN patients’ kidney function decline to normal levels
In a first, Otsuka’s Voyxact stabilizes IgAN patients’ kidney function decline to normal levels
Fierce Pharma · about 1 month ago
Fierce Pharma Asia—Legend CEO exits; Merck’s hush-hush PD-1xVEGF plan; Otsuka’s novel ADHD nod
Fierce Pharma Asia—Legend CEO exits; Merck’s hush-hush PD-1xVEGF plan; Otsuka’s novel ADHD nod
Fierce Pharma · about 1 month ago
FDA approves Otsuka’s ADHD drug Simtriyo, teeing up its ‘next major CNS launch’
FDA approves Otsuka’s ADHD drug Simtriyo, teeing up its ‘next major CNS launch’
Fierce Pharma · about 1 month ago
Otsuka’s ADHD approval opens up new drug class with $615M opportunity
Otsuka’s ADHD approval opens up new drug class with $615M opportunity
BioSpace · about 1 month ago
Otsuka Receives FDA Approval for First-in-Class SIMTRIYO® (centanafadine) for the Treatment of Attention-Deficit Hyperactivity Disorder (ADHD) in Adults and Pediatric Patients Aged 6 Years and Older
Otsuka Receives FDA Approval for First-in-Class SIMTRIYO® (centanafadine) for the Treatment of Attention-Deficit Hyperactivity Disorder (ADHD) in Adults and Pediatric Patients Aged 6 Years and Older
Yahoo Finance · about 2 months ago